Address: SERVIER POLSKA Sp. z o.o. ul. Jana Kazimierza 10, 01-248 Warszawa
Tel: (22) 594 90 00
Our entire activity is based on three key principles:
Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
The SERVIER Clinical Support Unit in Gidy (near Orleans) is the largest unit of its kind in Europe for the production of drugs for clinical trials.
Cardiovascular Disease:
Coversyl
Coveram
Hyperium
Natrilix SR
Preterax
Procoralan
Vastarel MR
Endocrinology:
Diamicron MR
Oncology:
Muphoran
Rheumatology:
Protelos
Venous disease:
Daflon 500
ENT:
Locabiotal
Pneumorel
Neurosciences:
Valdoxan
Stablon
Duxil
Trivastal Retard
Asthenia:
Arcalion
Colm Murphy, general plant manager of Anpharm, a key European production site for the Servier group, highlights major investments in recent years, such as the state-of-the-art QC Lab, and his…
Joanna Drewla, general manager of Servier Poland, discusses Polish healthcare challenges and looks at areas for improvement to create a sustainable balance for market access of innovative treatments. Furthermore, she…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and…
Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according…
“Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has…
The general director of Actavis Poland talks about competing in an intense generics market, and the company’s potential in Poland given the country’s 2012 Reimbursement Act. The year 2012 was…
AstraZeneca’s General Manager in Poland discuses AstraZeneca’s strategic realignment to become a highly specialized biotech company after 20 years of presence in Poland. He stresses the importance of the affiliate’s…
Novascon Pharmaceuticals is the second fastest growing company in the OTC/dietary supplement market in Poland. Its founder shares the reasons behind this success, including his strategy to sell their main…
Omega Pharma is a pharmacist champion and one of the fastest growing OTC companies in Poland. Its General Manager in Poland discusses the shift taking place with Pharmacies now becoming…
Schulke Poland’s General Manager wants the affiliate: “to be recognized as a high quality “one stop shop” for hygiene and disinfection. He also comments: “Poland is quite advanced in terms…
The department of innovation and industry under the Ministry of Economy has been preparing a new project called: “Pharmaceutical Industry Mapping.” Its leader hopes: “that the outcome of this exercise…
Bristol-Myers Squibb’s General Manager in Poland stresses the urgent need to allow more innovative drugs to fight against deadly diseases, especially in the field of immune-oncology which he says will:…
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Budget limitations in the Polish vaccine field are a handicap to improving patients’ lives as Sanofi Pasteur General Manager comments: “the National Health Fund’s budget for reimbursement is around EUR…
See our Cookie Privacy Policy Here
